CRI Clinical Innovator

Innovative immunotherapy clinical trials proposed by academic researchers are vitally important to improving patient outcomes. The CRI Clinical Innovator will support novel clinical studies that address areas of high unmet need in cancer and seek mechanistic insights into clinical response with a goal of predictive biomarker discovery. To maximize the impact of each clinical trial, CRI will advise on selected studies in a coordinated effort to optimize clinical trial design and translational studies.

The Clinical Innovator provides funding for clinician-scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. In addition to the merits of the clinical and scientific rationale, studies will be selected based on their novelty, feasibility, and clinical impact. Competitive applications will have a strong focus on yielding mechanistic insights into clinical response and potentials for biomarker discovery and/or validation. CRI will coordinate efforts on selected trials by advising on the following areas: standardizing sample collection, correlative assays, analysis, and data sharing, including, if applicable, deposition of immunogenomic data into the CRI iATLAS platform.

Financial Information

The Clinical Innovator will provide up to USD $1 million for each clinical trial it supports. The funds may be used for salary, supplies, patient costs, correlative assays, and data analyses. Payment will be structured into milestones to ensure that studies will advance and be brought to completion.

Eligibility

_You can learn more about this opportunity by visiting the funder's website._

• Candidates must be the Principal Investigator (PI) of the proposed study.
• CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools or research centers in the United States or abroad.

Ineligibility

• Please note that CRI does not support research at for-profit institutions.